Long non-coding RNA terminal differentiation-induced non-coding RNA regulates cisplatin resistance of choroidal melanoma by positively modulating extracellular signal-regulated kinase 2 via sponging microRNA-19b-3p

Li, Wei; Nie, Aiqing; Jin, Longyu; Cui, Yue; Xie, Ning; Liang, Gaohua

doi:10.1080/21655979.2021.2014618

Cited by 3 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, Li et al revealed that lncRNA TINCR was significantly increased in CDDP-resistant choroidal melanoma (CM) tissues and cells. TINCR overexpression in OCM-1 cells promoted proliferation and inhibited apoptosis by upregulating ERK-2 via sponging miR-19b-3p, leading to the enhancement of CDDP resistance in CM (184). Zhou et al found that lncRNA CCAT2 was upregulated in breast cancer (BC) tissues and 5-FU-resistant BC cell lines (MDA-MB-231, SKBR-3, MCF-7, and HCC-1937) after chemotherapy.…”

Section: Lncrnas Control the Cellular Death Pathways In Cancer Drug R...mentioning

confidence: 99%

“…revealed that lncRNA TINCR was significantly increased in CDDP-resistant choroidal melanoma (CM) tissues and cells. TINCR overexpression in OCM-1 cells promoted proliferation and inhibited apoptosis by upregulating ERK-2 via sponging miR-19b-3p, leading to the enhancement of CDDP resistance in CM ( 184 ). Zhou et al.…”

Section: Mechanisms Of Ncrnas In Mediating Cancer Drug Resistancementioning

confidence: 99%

See 1 more Smart Citation

Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications

Zhou

Jia

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Cancer is one of the most frequently diagnosed malignant diseases worldwide, posing a serious, long-term threat to patients’ health and life. Systemic chemotherapy remains the first-line therapeutic approach for recurrent or metastatic cancer patients after surgery, with the potential to effectively extend patient survival. However, the development of drug resistance seriously limits the clinical efficiency of chemotherapy and ultimately results in treatment failure and patient death. A large number of studies have shown that non-coding RNAs (ncRNAs), particularly microRNAs, long non-coding RNAs, and circular RNAs, are widely involved in the regulation of cancer drug resistance. Their dysregulation contributes to the development of cancer drug resistance by modulating the expression of specific target genes involved in cellular apoptosis, autophagy, drug efflux, epithelial-to-mesenchymal transition (EMT), and cancer stem cells (CSCs). Moreover, some ncRNAs also possess great potential as efficient, specific biomarkers in diagnosis and prognosis as well as therapeutic targets in cancer patients. In this review, we summarize the recent findings on the emerging role and underlying mechanisms of ncRNAs involved in cancer drug resistance and focus on their clinical applications as biomarkers and therapeutic targets in cancer treatment. This information will be of great benefit to early diagnosis and prognostic assessments of cancer as well as the development of ncRNA-based therapeutic strategies for cancer patients.

show abstract

Section: Lncrnas Control the Cellular Death Pathways In Cancer Drug R...mentioning

confidence: 99%

Section: Mechanisms Of Ncrnas In Mediating Cancer Drug Resistancementioning

confidence: 99%